Table 3.
entry | cmpnd | R1 | R2(D-ring) | tubulina IC50 (μM) | MCF-7b IC50 (nM) | activated HUVECc IC50 (nM) | quiescent HUVECd IC50 (nM) | selectivity ratioe |
---|---|---|---|---|---|---|---|---|
1 | 4 | - | - | 1.8 ± 0.2 | 2.9 | 3.6 | 3.9 | 1.1 |
2 | 12 | H | 1.3 ± 0.2 | 39 ± 18 | 45 | 41 | 0.9 | |
3 | 21 | H | 1.3 ± 0.04 | 42 ± 10 | 41 | 32 | 0.8 | |
4 | 25 | H | 1.9 ± 0.4 | 26±5 | 32 | 44 | 1.4 | |
5 | 26 | H | 2.3 (both runs) | 48 ± 10 | 30 | 34 | 1.1 | |
6 | 31a | H | H | 1.6 ± 0.2 | 55 ± 5 | 45 | 63 | 1.4 |
7 | 31b | OH | H | ND | 45 ± 15 | 83 | 322 | 3.9 |
8 | 27 | OH | 0.8 ± 0.2 | 4.0 ± 0.1 | 1.7 | 3.4 | 2.0 | |
9 | 8 | OH | Me | 3.0 ± 0.6 | 2.4 ± 2 | 0.31 | 25 | 81 |
10 | 28 | OH | 1.3 ± 0.07 | 1.0 ± 0.5 | 0.4 | 0.7 | 1.8 | |
11 | 24 | OiPr | ND | 42 ± 6 | 665 | 419 | 0.6 | |
12 | 33a | H | Br | ND | 495 ± 25 | 510 | 309 | 0.6 |
13 | 35 | H | ND | 71 ± 1 | 45 | 27 | 0.6 | |
14 | 45 | H | ND | 215 ± 15 | 484 | 405 | 0.8 | |
15 | 36 | OH | 8.7 ± 0.8 | 0.6 ± 0.2 | 3.6 | 3.4 | 0.9 | |
16 | 37 | OH | ND | 0.5 ± 0.2 | 0.31 | 0.36 | 1.2 | |
17 | 42 | OH | ND | ND | 2.6 | 3.3 | 1.3 | |
18 | 39 | OH | ND | ND | 0.38 | 2.3 | 6.0 | |
19 | 43 | OH | CN | ND | ND | 1.1 | 3.0 | 2.7 |
20 | 40 | OH | ND | ND | 2.6 | 2.3 | 0.9 | |
21 | 46 | OH | ND | ND | 29 | 36 | 1.2 | |
22 | 47 | OH | ND | ND | 3.1 | 2.9 | 0.9 | |
23 | 49 | OH | NH2 | ND | ND | 1.9 | 8.8 | 4.6 |
The tubulin concentration was 10 μM. Inhibition of extent of assembly was the parameter measured (n = 2).
Cells were grown for 48 h at 37 °C in a humidified 5%CO2 atmosphere. Cell protein was the parameter measured. At least two independent experiments were performed with each compound.
For activated growth conditions HUVEC cells were seeded at 2500 and 500 cells/well, respectively, and cultured in EGM-2 medium (Lonza) or F12K medium containing 0.03 mg/mL endothelial cell growth supplement.
For quiescent growth conditions HUVEC and HAAE-1 cells were seeded at 15 000 and 5000 cells/well, respectively, in basal medium (EBM-2 or F12K) containing 0.5% fetal calf serum and antibiotics.
Selectivity ratio (IC50 quiescent)/(IC50 activated).